Bringing the fundamentals into focus…
Back to Progyny, Inc.
How Progyny, Inc. stacks up
PGNY · against 387 other Healthcare companies of similar size
Valuation
63/ 100
Above the middle of the pack.
Ranked #155 of 388 · scores higher than 59% of peers
Bars: peers in each 10-point band of the valuation score45 peers with a valuation score of 60–69, including PGNY · Click a bar to see the companies
Why valuation scores 63?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its free cash flow yield, earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
- more operating profit (EBITDA) for the company's total value: stronger than 62% of peers. EBITDA yield: 6.2% vs peer median 4.0%
- higher earnings for the price paid: stronger than 64% of peers. Earnings yield: 3.5% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 91% of peers. Free cash flow yield: 8.0% vs peer median 0.0%
Metric by metric
Position: dot = PGNY, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PGNY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 377 reported | 3.2% | 1.8% | 59% | 30% | |
| EBITDA yieldHigher is better · 388 reported | 6.2% | 4.3% | 64% | 50% | |
| Free cash flow yieldHigher is better · 193 reported | 8.0% | -0.5% | 89% | 20% | |
| Book yieldHigher is better · 379 reported | 20.3% | 33.9% | 29% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PGNYScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score